Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 15/20 | 0.62 |
| ▸ | MAOB | P27338 | 14/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29440632 | 1.00 | MAOA (0.62) | MAOAMAOBTDP1L3MBTL1LMNA | |
| SCHEMBL87174 | 0.84 | MAPT (0.61) | MAOAMAOBLMNAGAAMAPT | |
| SCHEMBL29492902 | 0.84 | MAPT (0.61) | MAOAMAOBLMNAGAAMAPT | |
| SCHEMBL7813728 | 0.83 | MAOA (0.48) | MAOAMAOBTDP1L3MBTL1LMNA | |
| SCHEMBL12515596 | 0.81 | TDP1 (0.46) | MAOAMAOBTDP1L3MBTL1PARP1 | |
| SCHEMBL17398790 | 0.81 | TDP1 (0.54) | MAOAMAOBTDP1L3MBTL1PARP1 | |
| SCHEMBL30080977 | 0.80 | MAPT (0.60) | MAOAMAOBLMNAGAAMAPT | |
| SCHEMBL6585556 | 0.80 | MAPT (0.60) | MAOAMAOBLMNAGAAMAPT | |
| SCHEMBL9129183 | 0.78 | MAPT (0.58) | TDP1L3MBTL1GAAMAPT | |
| SCHEMBL7246016 | 0.78 | TDP1 (0.64) | MAOAMAOBTDP1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 252 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004089924-A1 | PROCESS FOR THE PREPARATION OF 5-BROMOPHTHALIDE | BROMINE COMPOUNDS LTD. (IL) | 2004-10-21 | — | — | WO | claimed |
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-12 | — | — | US | disclosed |
| US-12545653-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-01-27 | — | — | US | disclosed |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4605089-A1 | COMPOUNDS USEFUL IN MODULATING EGFR AND PI3K | Mekanistic Therapeutics LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2025101914-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS HAVING IMPROVED THERAPEUTIC INDEX AGAINST SOLID TUMORS | MEKANISTIC THERAPEUTICS LLC (US) | 2025-05-15 | — | — | WO | disclosed |
| EP-4522618-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES COMPOUNDS AS HPK1 INHIBITORS | Merck Patent GmbH (DE) | 2025-03-19 | — | — | EP | disclosed |
| EP-4251273-B1 | PHTHALAZINE DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | disclosed |
| US-12209079-B2 | IDO/TDO inhibitor | GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION (JP) | 2025-01-28 | — | — | US | disclosed |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2004-08-12 | — | — | US | disclosed |
| CN-1503795-A | Water-soluble triazole antifungal agents | ������������ʽ���� | 2004-06-09 | — | — | CN | disclosed |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1362856-A1 | WATER-SOLUBLE TRIAZOLE FUNGICIDE | Sankyo Company, Limited (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1007515-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | Abbott Laboratories (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010331-A1 | ARYLPYRIDAZINONES AS PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 1999-03-04 | — | — | WO | disclosed |
| EP-0101234-A1 | Therapeutic agent | The Boots Company PLC (GB) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209079-B2 | IDO/TDO inhibitor | IDO1, IDO2, TDO2 | MAOA 78/4885MAOB 60/4885TDP1 637/4885 |
| US-12545653-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARD, PPARG | MAOA 2388/4885MAOB 1634/4885TDP1 3385/4885 |
| US-12534455-B2 | Phthalazine derivatives as P2X3 inhibitors | P2RX3, P2RX5, P2RX7 | MAOA 1330/4885MAOB 2389/4885TDP1 3299/4885 |
| US-12622909-B2 | Allosteric EGFR inhibitors and methods of use thereof | EGFR, ERBB3, ERBB2 | MAOA 3384/4885MAOB 3189/4885TDP1 3589/4885 |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MAOA 667/4885MAOB 455/4885TDP1 3644/4885 |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MAOA 677/4885MAOB 479/4885TDP1 3633/4885 |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MAOA 677/4885MAOB 479/4885TDP1 3633/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | MAOA 3899/4885MAOB 3435/4885TDP1 2498/4885 |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | PTGS1, PTGIS, PTGS2 | MAOA 677/4885MAOB 479/4885TDP1 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.